The Universal Immune System Simulator – Multiple Sclerosis (UISS-MS) predicts the outcome of specific treatments in patients affected by a relapsing-remitting form of multiple sclerosis.
It provides decision-support to MS specialist about the best treatment based on the disease characteristics and on the immunological profile of the patient. It can be also used to run in silico trials of new treatments.
For the validation of this solution, UNICT will use data collected at third party Multiple Sclerosis Center, Neurology Unit, Garibaldi Hospital, Catania, Italy.
Data involves at least 150 adults affected by the two most common form of multiple sclerosis, i.e. primary progressing relapsing-remitting MS and secondary progressing MS.
All data will be collected with after the written approval of hospital local ethics committee (Comitato Etico dell’Azienda Ospedaliera “Garibaldi”), followed by patients informed consent to participate to this study for research purposes.
